SHATTUCK LABS INC
STTKNASDAQTrading Snapshot
- Day Range
- $5.36 – $5.67
- 52-Week Range
- $1.72 – $8.33
- Volume (shares)
- 83,005.465
- Avg Volume (shares)
- —
- Shares Outstanding
- 100.4M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- —
- P/E Ratio
- -11.4
- P/S Ratio
- 582.6x
- EPS (TTM)
- $-0.41
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +104.1%
SHATTUCK LABS INC
STTK
StockOtter · stockotter.spaceAbout SHATTUCK LABS INC
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Comparing Shattuck Labs (NASDAQ:STTK) & Exicure (NASDAQ:XCUR)
Shattuck Labs (NASDAQ: STTK - Get Free Report) and Exicure (NASDAQ: XCUR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-clas
Shattuck Labs (NASDAQ:STTK) Stock Falls 5.3% – Should You Sell?
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) shares fell 5.3% during mid-day trading on Monday. The company traded as low as $6.33 and last traded at $6.3760. 599,094 shares traded hands during mid-day trading, a
Shattuck Labs (NASDAQ:STTK) Shares Climb 11.9% – Here’s Why
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report)'s stock price traded up 11.9% on Wednesday. The stock traded as high as $6.89 and last traded at $7.3150. 221,063 shares were traded during mid-day trading, a decline
Comparing MDxHealth (NASDAQ:MDXH) & Shattuck Labs (NASDAQ:STTK)
Shattuck Labs (NASDAQ: STTK - Get Free Report) and MDxHealth (NASDAQ: MDXH - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strengt
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
– RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028 – – H